ROTH Capital Partners Acts as Co-Manager for
bluebird bio, Inc. (BLUE) in its $500 Million Follow-On

For more information please contact:

Investment Banking
John Chambers
Vice-Chairman and
Head of Healthcare Investment Banking
(646) 358-1901
jchambers@roth.com

Michael Margolis, R.Ph.
Managing Director
(646) 358-1902
mmargolis@roth.com

Warren Dunnavant II
Senior Vice President
(646) 358-1903
wdunnavant@roth.com

Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703

agurewitz@roth.com

Nazan Akdeniz
Senior Vice President
(949) 720-5740

nakdeniz@roth.com

Lou Ellis
Senior Vice President
(949) 720-5739

lellis@roth.com

Transaction Information

On June 23, 2015 bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, announced the pricing of an underwritten public offering of 2,941,176 shares of its common stock at a public offering price of $170.00 per share.

 

bluebird bio intends to use the proceeds of this offering primarily to advance its immuno-oncology programs, build its commercial infrastructure to support a potential conditional commercial launch in Europe, expand its manufacturing capabilities to support ongoing and anticipated development and commercial efforts and initiate clinical studies of LentiGlobin in adult, adolescent and pediatric subjects with beta-thalassemia major. The balance will be used for general and administrative expenses, potential future development programs, early-stage research and development, capital expenditures and working capital and other general corporate purposes.

 

ROTH Capital Partners acted as co-manager for the offering.

    

About bluebird bio, Inc. (Nasdaq: BLUE)

With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapy. bluebird bio’s clinical programs include Lenti-D™, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy, and LentiGlobin®, currently in three clinical studies: a global Phase 1/2 study, called the Northstar Study, for the treatment of beta-thalassemia major; a single-center Phase 1/2 study in France (HGB-205) for the treatment of beta-thalassemia major or severe sickle cell disease; and a separate U.S. Phase 1 study for the treatment of sickle cell disease (HGB-206). bluebird bio also has ongoing preclinical CAR T immuno-oncology programs, as well as discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies.

 

bluebird bio has operations in Cambridge, Massachusetts, Seattle, Washington, and Paris, France. (Source: Company Press Release 6/23/15)

    

About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. and Hong Kong. For more information on ROTH, please visit www.roth.com.

About ROTH Investment Banking Venture Finance Institutional Sales & Trading
Research Corporate Services Marketing & Conferences Press Room

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2015.